Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Overexpression FGFR2b”

6 trials

Showing 6 of 6 results

Testing effectiveness (Phase 2)WithdrawnNCT06967987
What this trial is testing

Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

Who this might be right for
Gastric and Gastro-oesophageal Junction (GEJ) AdenocarcinomasOverexpression FGFR2b
Institut Cancerologie de l'Ouest
Early research (Phase 1)Ended earlyNCT05267470
What this trial is testing

Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Who this might be right for
Squamous-Cell Non-Small-Cell Lung Cancer
Amgen 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT05322577
What this trial is testing

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Amgen 72
Testing effectiveness (Phase 2)Study completedNCT05325866
What this trial is testing

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Solid Tumors
Amgen 260
Large-scale testing (Phase 3)Active Not RecruitingNCT05111626
What this trial is testing

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 515
Large-scale testing (Phase 3)Active Not RecruitingNCT05052801
What this trial is testing

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 547

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation